Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.

Abstract

1,2-Distigmasterylhemisuccinoyl-sn-glycero-3-phosphocholine (DSHemsPC) is a new lipid in which two molecules of stigmasterol (an inexpensive plant sterol) are covalently linked via a succinic acid to glycerophosphocholine. Our previous study revealed that liposome (Lip)-intercalated amphotericin B (AMB) prepared from DSHemsPC (DSHemsPC-AMB-Lip) possesses excellent colloidal properties and in vitro antifungal and antileishmanial activities similar to those of the liposomal AMB preparation AmBisome. The aim of this study was to determine the biodistribution and evaluate the antileishmanial effects of DSHemsPC-AMB-Lip in Leishmania major-infected BALB/c mice. The serum profile and tissue concentrations of AMB were similar in DSHemsPC-AMB-Lip- and AmBisome-treated mice after intravenous (i.v.) injection. Multiple i.v. doses of the micellar formulation of AMB (Fungizone; 1 mg/kg of body weight), DSHemsPC-AMB-Lip (5 mg/kg), and AmBisome (5 mg/kg) were used in L. major-infected BALB/c mouse models of early and established lesions. In a model of the early lesions of cutaneous leishmaniasis (CL), the results indicated that the level of footpad inflammation was significantly (P < 0.001) lower in mice treated with DSHemsPC-AMB-Lip and AmBisome than mice treated with empty liposomes or 5% dextrose. The splenic and footpad parasite load was also significantly (P < 0.001) lower in these groups of mice than in control mice that received 5% DW or free liposome. The in vivo activity of DSHemsPC-AMB-Lip was comparable to that of AmBisome, and both provided improved results compared to those achieved with Fungizone at the designated doses. The results suggest that systemic DSHemsPC-AMB-Lip administration may be useful for the treatment of leishmaniasis, and because it costs less to produce DSHemsPC-AMB-Lip than AmBisome, DSHemsPC-AMB-Lip merits further investigation.

• Authors: Maryam Iman, Zhaohua Huang, Seyedeh Hoda Alavizadeh, Francis C Szoka Jr, Mahmoud R Jaafari
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 61 Issue 9 (09 2017) ISSN: 1098-6596 [Electronic] United States
• PMID: 28630182 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017 American Society for Microbiology.

Chemical References

• 1,2-distigmasterylhemisuccinoyl-glycero-3-phosphocholine
• Antiprotozoal Agents
• Drug Carriers
• Liposomes
• Phosphatidylcholines
• liposomal amphotericin B
• Amphotericin B
• Stigmasterol

Topics

• Amphotericin B (pharmacokinetics, therapeutic use)
• Animals
• Antiprotozoal Agents (pharmacokinetics, therapeutic use)
• Disease Models, Animal
• Drug Administration Routes
• Drug Carriers (therapeutic use)
• Female
• Leishmania major (drug effects, pathogenicity)
• Leishmaniasis, Cutaneous (drug therapy, parasitology)
• Liposomes (therapeutic use)
• Mice
• Mice, Inbred BALB C
• Parasite Load
• Phosphatidylcholines (pharmacokinetics, therapeutic use)
• Spleen (parasitology)
• Stigmasterol (analogs & derivatives, pharmacokinetics, therapeutic use)